Integrated BioTherapeutics
Chemicals & Related Products · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4 Research Ct Ste 300, Rockville, Maryla...Phone Number
(301) 515-0324Revenue
$9.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Integrated BioTherapeutics
IBT develops vaccines and immunotherapies for bacterial and viral infectious diseases. The Company's lead vaccine product, IBT-V02 is a first-in-class multi-component vaccine against Staphylococcus aureus. Supported by CARB-X and by Novo Holding's Repair Impact Fund, IBT-V02 is currently undergoing cGMP manufacturing and IND-enabling studies, with initiation of clinical trials anticipated in late 2022. IBT and its subsidiary IBV (http://www.integratedbiotherapeuticvaccines.com) immunotherapeutic pipeline includes monoclonal antibodies for the treatment of the array of viruses that cause hemorrhagic fever. IBT also is developing product candidates for the treatment of S. aureus, anthrax, and Clostridium difficile, based on its proprietary Infection Site Targeted Antitoxin Antibody (ISTAb) technology.Explore more
Integrated BioTherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Integrated BioTherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Integrated BioTherapeutics
Check out if Integrated BioTherapeutics is spiking on competitors!
Click to see if Integrated BioTherapeutics had a recent Job posting/layoffs
Check if Integrated BioTherapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Integrated BioTherapeutics has new funding data
Product Launch: Get notified when Integrated BioTherapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Integrated BioTherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Integrated BioTherapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Integrated BioTherapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Integrated BioTherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Integrated BioTherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Integrated BioTherapeutics.
Integrated BioTherapeutics financials insights
Gather financial insights about Integrated BioTherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
Integrated BioTherapeutics Tech Stack
A closer look at the technologies used by Integrated BioTherapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Funding
Integrated BioTherapeutics has received an SBA PPP loan for $350,000-1 million from Capital One.
Funding
Integrated BioTherapeutics Inc has received an SBA PPP loan for $350,000-1 million from Capital One, National Association.
Funding
Integrated BioTherapeutics News & Media
Integrated Biotherapeutics Awarded $3.55M Grant to Study Immune Correlates of Protection Against Recurrent Staphylococcal Infection
Study is expected to provide insights into mechanisms of protection against staph infection. IBT and its subsidiary Integrated BioTherapeutic Vaccines (IBV) are developing IBT-V02, a novel vaccine for S. aureus infections with support from CARB-X and Novo Holdings. IBT-V02 will enter Phase 1 clinical trial this year. (PRWeb March 24, 2022) Read the full story at https://www.prweb.com/releases/integrated_biotherapeutics_awarded_3_55m_grant_to_study_immune_correlates_of_protection_against_recurrenIntegrated BioTherapeutics Inc. Awarded $16.3M Contract from the National Institute of Allergy and Infectious Diseases to Develop a Treatment for Marburg Virus Disease
Contract to support manufacturing and a Phase 1 clinical trial. (PRWeb May 19, 2021) Read the full story at https://www.prweb.com/releases/integrated_biotherapeutics_inc_awarded_16_3m_contract_from_the_national_institute_of_allergy_and_infectious_diseases_to_develop_a_treatment_for_marburg_virus_disease/prweb17943522.htmGary Nabors, Ph.D. Joins Integrated BioTherapeutics Inc. as Executive...
IBT is pioneering development of the first multivalent toxoid-based vaccine against Staphylococcus aureus as well as immunotherapies for several viral diseases. (PRWeb September 14, 2020) Read the full story at https://www.prweb.com/releases/gary_nabors_ph_d_joins_integrated_biotherapeutics_inc_as_executive_vice_president_and_chief_development_officer/prweb17389568.htmImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)
VICTORIA, BC, June 4, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced it is collaborating, pursuant to an agreement dated...
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Integrated BioTherapeutics
Sign Up For FreeTo access detailed company insights
IBT develops vaccines and immunotherapies for bacterial and viral infectious diseases. The Company's lead vaccine product, IBT-V02 is a first-in-class multi-component vaccine against Staphylococcus aureus. Supported by CARB-X and by Novo Holding's Repair Impact Fund, IBT-V02 is currently undergoing cGMP manufacturing and IND-enabling studies, with... Read More
